Anti-CEBP Delta/CEBPD antibody

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CEBP Delta also known as CEBPD is a transcription factor belonging to the CCAAT/enhancer-binding protein family. This protein has a molecular mass of approximately 28 kDa. It is expressed in various tissues including liver adipose tissue and the immune system reflecting its involvement in distinct physiological processes. CEBPD contains a basic leucine zipper domain allowing it to bind to specific DNA sequences. It acts as a regulator of gene expression by influencing transcriptional activity thereby playing a significant role in controlling cellular differentiation and metabolic processes.

Biological function summary

CEBP Delta participates in multiple cellular functions including cell cycle regulation and immune response. It modulates proliferation differentiation and apoptosis being important for normal and stress-induced cellular functions. CEBPD forms homodimers or heterodimers with other members of the CEBP family enhancing its functional diversity. This dimerization allows CEBPD to adapt its regulatory role depending on the specific cellular environment and stimuli contributing to metabolic homeostasis and immune functions.

Pathways

CEBP Delta plays a role in pathways related to inflammatory responses and metabolic regulation. It is involved in the NF-κB pathway which is critical for the immune system's response to infection and inflammation working alongside proteins like RELA and NFKB1. Additionally it affects metabolic pathways by regulating genes responsible for lipid and glucose metabolism an action interconnected with other transcription factors like PPARs. Through these pathways CEBPD influences cellular responses to stress and energy requirements.

CEBP Delta has been implicated in cancer development and inflammatory diseases. Its dysregulation can contribute to tumorigenesis as CEBPD affects cell proliferation and apoptosis processes often disrupted in cancer. Research suggests a connection between CEBPD and the tumor-suppressing protein p53 indicating a possible regulatory relationship significant in cancer pathways. Furthermore abnormal expression of CEBPD associates with inflammatory disorders such as rheumatoid arthritis where it intersects with cytokines impacting the inflammatory response and joint degradation.